Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)

1. **Your Name:** Edward M. Kerwin MD.		
2. **Are you testifying on behalf of the Federal, or a State or local government entity?**	Yes	~~No~~ X
3. **Are you testifying on behalf of an entity that is not a government entity?**	Yes	~~No~~ X
4. **Other than yourself, please list which entity or entities you are representing:** Representing myself.		
5. **Please list any Federal grants or contracts (including subgrants or subcontracts) that <u>you or the entity you represent have received</u> on or after October 1, 2009:** None.		
6. **If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing:** N/A		
7. **If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?** N/A	Yes	No
8. **If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2009, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed:** N/A		
9. **Please attach your curriculum vitae to your completed disclosure form.**		

Signature: [redacted] **Date:** 16 JULY 2012

Edward Kerwin, MD
Senior Medical Director, Allergy & Asthma Center of Southern Oregon, PC
3860 Crater Lake Ave., Medford, OR 97504
Ph. 541-858-1003 Fax: 541-857-4499

Edward Kerwin, MD is an Allergy Asthma and Clinical Research Physician specializing in the treatment of Asthma and COPD patients. Dr. Kerwin has acted as a principal investigator on over 300 clinical trials of new inhaled medications for Asthma and COPD, including some 50 trials studying new HFA (Hydrofluoroalkane) inhalers used to replace older CFC (Chlorofluorocarbon) inhalers. Dr. Kerwin is an independent physician, and is not an employee of any pharmaceutical company, but performs research for many pharmaceutical companies.